Ex­clu­sive: Gen­mab's CEO touts M&A po­ten­tial as it inks first part­ner­ship out­side can­cer

Slow­ly and steadi­ly, the Dan­ish an­ti­body spe­cial­ist Gen­mab has grown in­to a $27 bil­lion mar­ket cap pow­er­house dri­ven by can­cer re­search.

Now, Gen­mab is mak­ing moves be­yond on­col­o­gy, an­nounc­ing Mon­day a mul­ti-year re­search deal with the Dutch drug­mak­er ar­genx to en­ter the mas­sive im­munol­o­gy and in­flam­ma­tion mar­ket, Gen­mab CEO Jan van de Winkel told End­points News.

The com­pa­nies will even­ly split ex­pens­es and po­ten­tial up­side and start re­search­ing two undis­closed tar­gets in can­cer and im­munol­o­gy, though it could grow to more tar­gets over time, van de Winkel said. Oth­er col­lab­o­ra­tions with BioN­Tech and J&J’s Janssen have fol­lowed such tra­jec­to­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER